MARKET

AVEO

AVEO

Aveo
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.37
+0.18
+3.47%
After Hours: 5.13 -0.24 -4.47% 16:05 12/04 EST
OPEN
5.21
PREV CLOSE
5.19
HIGH
5.41
LOW
5.12
VOLUME
264.33K
TURNOVER
--
52 WEEK HIGH
10.71
52 WEEK LOW
2.230
MARKET CAP
154.71M
P/E (TTM)
-3.4769
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
AVEO Oncology to Present at the Stifel 2020 Virtual Healthcare Conference
AVEO Oncology (Nasdaq: AVEO) today announced that Michael Bailey, president and chief executive officer of AVEO, will present at the Stifel 2020 Virtual Healthcare Conference on Monday, November 16, 2020 at 11:20 a.m. Eastern Time.
Business Wire · 11/10 12:00
AVEO Oncology to Present at the Stifel 2020 Virtual Healthcare Conference
AVEO Oncology (Nasdaq: AVEO) today announced that Michael Bailey, president and chief executive officer of AVEO, will present at the Stifel 2020 Virtual Healthcare Conference on Monday, November 16, 2020 at 11:20 a.m. Eastern Time.
BusinessWire · 11/10 09:00
AVEO Oncology Reports Third Quarter 2020 Financial Results and Provides Business Update
--- Ficlatuzumab Worldwide Rights Regained; Final Results from Open Label Randomized Phase 2 HNSCC Study and Plans for Pivotal Program Expected in the Middle of 2021 -
BusinessWire · 11/09 18:05
AVEO Oncology and EUSA Pharma Announce Annals of Oncology Publication of Data from Phase 1b/2 TiNivo Study in Renal Cell Carcinoma
AVEO Oncology (NASDAQ: AVEO) and EUSA Pharma today announced that previously reported results from the Phase 1b/2 TiNivo study of oral (PO) tivozanib, AVEO's next-generation vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor (TKI) drug candidate, in combination with intravenous (IV) nivolumab (OPDIVO(R), Bristol-Myers Squibb), an immune checkpoint, or PD-1, inhibitor, for the treatment of advanced or metastatic renal cell carcinoma (mRCC), were published in Annals of Oncology. The article, titled "TiNivo: Safety and Efficacy of Tivozanib-Nivolumab Combination Therapy in Patients with Metastatic Renal Cell Carcinoma", is available online first via this link.
BusinessWire · 11/05 09:00
AVEO Oncology Announces Appointment of David W. Crist as Vice President of Sales
Business Wire · 10/19 12:00
AVEO Oncology Announces Appointment of David W. Crist as Vice President of Sales
AVEO Oncology (Nasdaq: AVEO) today announced the appointment of David Crist as Vice President of Sales. In this role, Mr. Crist will be responsible for building out AVEO's sales force in anticipation of the potential approval and launch of tivozanib, the Company's next-generation vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI), as a treatment for relapsed or refractory renal cell carcinoma.
BusinessWire · 10/19 11:00
Armata's AP-PA02 Gets IND Clearance by FDA to Initiate Study
Armata's (ARMP) AP-PA02 IND application gets clearance from the FDA to initiate a phase Ib/IIa study for the treatment of Pseudomonas aeruginosa infections.
Zacks · 10/16 13:58
AnaptysBio Shares Up on Positive Top-Line Psoriasis Data
AnaptysBio (ANAB) reports positive top-line data from an interim analysis of its phase II GALLOP study on imsidolimab for the treatment of moderate-to-severe generalized pustular psoriasis.
Zacks · 10/14 15:03
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AVEO. Analyze the recent business situations of Aveo through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AVEO stock price target is 11.25 with a high estimate of 17.00 and a low estimate of 7.00.
EPS
Institutional Holdings
Institutions: 128
Institutional Holdings: 11.26M
% Owned: 39.07%
Shares Outstanding: 28.81M
TypeInstitutionsShares
Increased
22
1.14M
New
27
-1.33M
Decreased
14
1.27M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.89%
Pharmaceuticals & Medical Research
+1.72%
Key Executives
President/Chief Executive Officer/Director
Michael Bailey
Chief Financial Officer
Erick Lucera
Senior Vice President/General Counsel
Karuna Rubin
Other
Michael Needle
Lead Director/Independent Director
Kenneth Bate
Independent Director
Anthony Evnin
Independent Director
Gregory Mayes
Independent Director
Scarlett Spring
Independent Director
Robert Young
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About AVEO
AVEO Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's platform delivers insights into cancer and related disease. The Company's product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors. Tivozanib is designed to optimize VEGF blockade while minimizing off-target toxicities. Ficlatuzumab is a Hepatocyte Growth Factor (HGF) inhibitory antibody. AV-203 is an anti-ErbB3 monoclonal antibody with ErbB3 affinity. Its preclinical studies suggest that neuregulin1 (NRG1) levels predict AV-203 antitumor activity in preclinical models. AV-380 is a humanized Immunoglobulin G 1 (IgG1) inhibitory monoclonal antibody. AV-380 targets growth differentiating factor 15 (GDF15).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of AVEO Pharmaceuticals, Inc. stock information, including NASDAQ:AVEO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AVEO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AVEO stock methods without spending real money on the virtual paper trading platform.